

**Table 4. Comparison of the patient characteristics between irAE (+) and (-) groups among the 28 patients accompanied with autoimmune diseases (AI)**

|                                                     | irAE (+), n (%) | irAE (-), n (%) |
|-----------------------------------------------------|-----------------|-----------------|
| <b>N</b>                                            | 16 (57.1)       | 12 (42.9)       |
| <b>Gender (male)</b>                                | 12 (75.0)       | 7 (58.3)        |
| <b>Age (median)</b>                                 | 70.5 (47-90)    | 66 (51-90)      |
| <b>PS</b>                                           |                 |                 |
| 0                                                   | 7 (43.8)        | 6 (50.0)        |
| 1                                                   | 6 (37.5)        | 5 (41.7)        |
| 2                                                   | 3 (18.8)        | 1 (8.3)         |
| 3                                                   | 0 (0.0)         | 0 (0.0)         |
| 4                                                   | 0 (0.0)         | 0 (0.0)         |
| <b>Type of cancer</b>                               |                 |                 |
| Lung                                                | 10 (62.5)       | 5 (41.7)        |
| Digestive tract                                     | 0 (0.0)         | 1 (8.3)         |
| Head & Neck                                         | 0 (0.0)         | 2 (16.7)        |
| Melanoma                                            | 1 (6.3)         | 0 (0.0)         |
| Urothelial                                          | 1 (6.3)         | 2 (16.7)        |
| Liver                                               | 2 (12.5)        | 0 (0.0)         |
| Merkel cell ca.                                     | 2 (12.5)        | 0 (0.0)         |
| Malignant mesothelioma                              | 0 (0.0)         | 1 (8.3)         |
| MSI-H tumor                                         | 0 (0.0)         | 1 (8.3)         |
| <b>Type of ICI</b>                                  |                 |                 |
| Anti-PD-1 Ab                                        | 9 (56.3)        | 9 (75.0)        |
| Anti-PD-L1 Ab                                       | 7 (43.8)        | 2 (16.7)        |
| Anti-PD-1& Anti-CTLA4 Ab                            | 0 (0.0)         | 1 (8.3)         |
| <b>Combined agent</b>                               |                 |                 |
| None                                                | 10 (62.5)       | 10 (83.3)       |
| Cytotoxic agents                                    | 4 (25.0)        | 2 (16.7)        |
| Molecular target agents                             | 2 (12.5)        | 0 (0.0)         |
| <b>Best overall response</b>                        |                 |                 |
| CR                                                  | 1 (6.3)         | 1 (8.3)         |
| PR                                                  | 7 (43.8)        | 4 (33.3)        |
| SD                                                  | 5 (31.3)        | 3 (25.0)        |
| PD                                                  | 1 (6.3)         | 3 (25.0)        |
| NE                                                  | 2 (12.5)        | 1 (8.3)         |
| <b>Type of AI</b>                                   |                 |                 |
| RA                                                  | 5 (25.0)        | 6 (50.0)        |
| Hashimoto's thyroiditis                             | 4 (20.0)        | 0 (0.0)         |
| Basedow's disease                                   | 1 (5.0)         | 2 (16.7)        |
| SLE*                                                | 2 (10.0)        | 0 (0.0)         |
| SjS                                                 | 0 (0.0)         | 1 (8.3)         |
| ITP                                                 | 2 (10.0)        | 1 (8.3)         |
| Pemphigoid                                          | 1 (5.0)         | 0 (0.0)         |
| Psoriasis vulgaris                                  | 1 (5.0)         | 0 (0.0)         |
| PBC                                                 | 1 (5.0)         | 0 (0.0)         |
| Palmoplantar pustulosis                             | 1 (5.0)         | 0 (0.0)         |
| UC                                                  | 2 (10.0)        | 1 (8.3)         |
| Crohn's disease                                     | 0 (0.0)         | 1 (8.3)         |
| <b>Type of drug for AI at the time of ICI start</b> |                 |                 |
| Steroid                                             | 4 (25.0)        | 2 (16.7)        |
| Methotrexate                                        | 1 (6.3)         | 1 (8.3)         |
| Others                                              | 3 (18.8)        | 4 (33.3)        |
| None                                                | 8 (50.0)        | 5 (41.7)        |

\* accompanied with scleroderma

PBC; primary biliary cirrhosis, UC; ulcerative colitis, SjS; Sjogrens's syndrome, ITP; idiopathic

thrombocytopenic purpula